ESC 365 - Empagliflozin ameliorates the cardiac energy-deficient state, improves cardiac function and reduces myocardial cellular volume in patients with type 2 diabetes

EACVI Premium Access

Empagliflozin ameliorates the cardiac energy-deficient state, improves cardiac function and reduces myocardial cellular volume in patients with type 2 diabetes

Session: Recent trials and breaking studies

Topic: Epidemiology, Prognosis, Outcome

Speaker: Doctor S. Thiru (Leeds, GB)

Event: EuroCMR 2021

Congress Presentation

Add to my library

About the speaker

Doctor Sharmaine Thiru

Leeds General Infirmary, Leeds (United Kingdom of Great Britain & Northern Ireland)

1 presentation

0 follower

3 more presentations in this session

Cost-Minimization analysis for cardiac revascularization in 12 healthcare systems based on the EuroCMR/SPINS registries

Speaker: Doctor K. Moschetti (Lausanne, CH)

Large-scale, multi-vendor, multi-protocol, quality-controlled analysis of clinical cine CMR using artificial intelligence

Speaker: Doctor J. Mariscal Harana (London, GB)

Long-term Prognostic Value of Cardiovascular Magnetic Resonance Imaging in Patients with Suspected Cardiac Tumor: A Multicenter Study with 4,285 Patient-years of Follow-up

Speaker: Associate Professor C. Shenoy (Minneapolis, US)

Access the full session

Recent trials and breaking studies

Speakers: Doctor S. Thiru, Doctor K. Moschetti, Doctor J. Mariscal Harana, Associate Professor C. Shenoy

About the event

EuroCMR 2021

6 May - 8 May 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources